Proveca Ltd
Dominic Ogden has a diverse work experience spanning across multiple industries and roles. Their most recent role is with Proveca Ltd as a Business Analyst starting in April 2021. Prior to that, they worked at Biogen as a Data & Analytics Associate from June 2019 to December 2020. Before joining Biogen, Dominic was employed by AbbVie as a Data Visualization Lead from May 2016 to May 2019. Dominic started their career at Vodafone in April 2010 as a Business Analyst and later became an Operations Manager, responsible for line management, cost reduction, and business improvements. Dominic also worked at Cable & Wireless as a Technical Engineer from June 2008 to April 2010 and at Principles Retail as an Assistant Manager from January 1993 to January 1997.
Dominic Ogden's education history begins with their time at Gillotts School in Henley-on-Thames from 1981 to 1986. There is no mention of a degree or field of study during this period. Following that, they attended Henley College from 1986 to 1989, where they completed their high school education and likely obtained their A Levels. In 1989, Dominic enrolled at the University of Exeter and graduated in 1992 with a BA Combined Honours degree in History & Archaeology. Finally, from 2012 to 2016, they pursued a Master of Business Administration (M.B.A.) at The Open University, specializing in Business Administration and Management, General.
Proveca Ltd
Proveca Ltd is a pharmaceutical company specialising in identifying, researching and licensing off-patent medicines with unmet priority health care needs, with a focus on the paediatric market. By developing the necessary formulations and clinical data required to obtain a Paediatric Use Marketing Authorisation (PUMA) these drugs will benefit froma period of 10 years' market protection (8 years of data and market protection plus 2 further years of market protection). In addition, where appropriate, Orphan Drug status (Orphan Drug) will be sought which affords a period of 10 years' market exclusivity to run concurrently.Value will be realised through commercialisation of the licensed medicine or an outright sale of the licence to a larger pharmaceutical company.